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ABSTRACT
Many of the earliest stem cell studies were conducted on
cells isolated from tumors rather than from embryos. Of
particular interest was research on embryonic carcinoma
cells (EC), a type of stem cell derived from teratocarci-
noma. The EC research laid the foundation for the later
discovery of and subsequent work on embryonic stem cells
(ESC). Both ESC isolated from the mouse (mESC) and
then later from humans (hESC) shared not only pluripo-
tency with their EC cousins, but also robust tumorigenic-
ity as each readily form teratoma. Surprisingly, decades
after the discovery of mESC, the question of what drives
ESC to form tumors remains largely an open one. This
gap in the ﬁeld is particularly serious as stem cell tumori-
genicity represents the key obstacle to the safe use of stem
cell-based regenerative medicine therapies. Although some
adult stem cell therapies appear to be safe, they have only
a very narrow range of uses in human disease. Our under-
standing of the tumorigenicity of human induced pluri-
potent stem cells (IPSC), perhaps the most promising
modality for future patient-speciﬁc regenerative medicine
therapies, is rudimentary. However, IPSC are predicted to
possess tumorigenic potential equal to or greater than that
of ESC. Here, the links between pluripotency and tumori-
genicity are explored. New methods for more accurately
testing the tumorigenic potential of IPSC and of other
stem cells applicable to regenerative medicine are pro-
posed. Finally, the most promising emerging approaches
for overcoming the challenges of stem cell tumorigenicity
are highlighted. STEM CELLS 2009;27:1050–1056
Disclosure of potential conﬂicts of interest is found at the end of this article.
TUMORS,N OT EMBRYOS INITIATED THE
DEVELOPMENT OF THE EMBRYONIC STEM
CELLS FIELD
The link between stem and tumor cells in science is a very
old one. The earliest research on highly pluripotent stem
cells was conducted not on normal stem cells, but instead on
embryonic carcinoma cells (EC) derived from teratocarci-
noma. EC had unusual stem-like properties that attracted a
great deal of attention at the time, including a surprising
degree of plasticity. Teratocarcinoma and its benign cousin
teratoma are the best examples of tumors with substantial
populations of pluripotent stem cells as well as differentiated
tissues. It may not be widely appreciated that when embry-
onic stem cells (ESC) were ﬁrst isolated [1, 2] from the
mouse by two independent groups more than a decade after
the discovery of EC, the existing knowledge base and
reagents related to EC played pivotal roles. In fact, in one
case ESC were established and cultured in EC conditioned
media [2]. It was also noted that ESC expressed the same
markers as EC. Thus, EC were the touchstone to which ESC
were initially compared and the fact that ESC shared so
many properties with established EC lines was argued as
validation that ESC were pluripotent stem cells. ESC and
EC could be differentiated into a myriad of cell types [3]
and formed teratoma with many diverse tissues, suggesting
the exciting conclusion that both these cell types had robust
pluripotency (reviewed in [4]).
However, these studies also raised an important, still
largely unanswered question. Why would ESC, supposedly
normal counterparts to EC, also have the ability to cause
tumors? The simplest but most troublesome answer is that
ESC and EC are in fact, as was originally assumed, quite sim-
ilar types of cells. Removing the inner cell mass (ICM) from
the context of the early embryo and enforcing the culture of
ICM cells in vitro produces a new cell type that does not nor-
mally exist in nature, that is, ESC. Although ESC mirror
many of the normal, desired properties of the ICM cells such
as near totipotency, they are not simply an in vitro manifesta-
tion of ICM cells but also almost certainly contain distinct
properties, some of a more tumorigenic nature. The fact that
the ESC ﬁeld began with and in some ways depended on the
much earlier discovery of EC highlights the intimate link
between stem and tumor cells as well as between pluripotency
and tumorigenicity.
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cells transition to ESC in vitro may be driven by the method
of creating ESC via selecting for those unique ICM cells that
can be forced to grow in vitro. This selective process is pre-
dicted to go hand-in-hand with epigenetic changes that enable
such growth. Thus, driving ICM cells to become ESC may be
at the same time creating a cell type that is inescapably also
pushed toward a tumorigenic phenotype. Just how different
ESC are from ICM cells remains an intriguing question. It is
important to note that even transplants of whole early
embryos can drive teratoma formation as well so some of the
forces driving teratoma formation are intrinsic to ICM cells
and not because of their in vitro growth to produce ESC.
THE TERATOMA ASSAY:B OTH A
PLURIPOTENCY AND A TUMOR ASSAY
It is remarkable that, to date, one of the most common assays
for demonstrating and studying the pluripotency of stem cells,
including induced pluripotent stem cells (IPSC), is the tera-
toma assay. Often this is referred to as a pluripotency assay,
but of course it is also a tumor assay. The fact that a key
assay of ‘‘stemness’’ is also a tumor assay further illustrates
the strong link between stem and tumor cells, a reality too
rarely discussed in the ﬁeld when interpreting results from ter-
atoma assays. Even ignoring for the moment the ability of
ESC and IPSC to produce malignant tumors in some cases [5,
6], the production of benign teratoma as a side effect in
humans given a hypothetical regenerative medicine therapy in
the future, would be unacceptable. Such tumors could be
numerous and would prove highly destructive to surrounding
normal or regenerating tissue. Thus, a key concept is that
stem cells, even those with potent self-renewal and pluripo-
tency, will almost certainly never be directly used in regener-
ative medicine if they cannot be proven to lack the ability to
cause teratoma in mice.
WHAT IS THE MOLECULAR BASIS OF THE
TUMORIGENICITY OF NORMAL STEM CELLS?
Recent studies indicate that many of the same master pro-
gramming elements are at work in both stem cells and tumor
cells [7–10]. This shared molecular machinery suggests that
untangling the determinants of pluripotency from the pro-
gramming responsible for tumorigenicity is going to be a
major challenge. The links between pluripotency and tumori-
genicity are exempliﬁed by the fact that many of the genes
used to produce IPSC are either outright established onco-
genes such as Myc and KLF4 [11–13] or are in various ways
linked to tumorigenesis such as Sox2 [14], Nanog [9], and
Oct3 [15]. But perhaps no molecule embodies the interwoven
nature of the pluripotency and tumorigenicity programs more
than Myc itself. Overexpression of the Myc family of proto-
oncogenes is linked with an array of human tumors and ele-
vated Myc expression may have some role in all human can-
cer [16]. Not only is Myc expression itself shared between
stem and tumor cells, but distinct groups of Myc regulated
target genes are coexpressed in both malignant tumors and
ESC [10].
Myc was one of the ﬁrst oncogenes discovered and there
are literally thousands of papers studying the function of
excess Myc in cancer. However, it has only been more
recently that the normal role of Myc in stem cell biology has
been discerned. Loss of function models reducing or eliminat-
ing expression of Myc genes in stem cells consistently show
disruption of the function of those stem cells [17, 18] and c-
Myc appears to be essential for normal STAT signaling in
mouse ESC (mESC) required for self-renewal and pluripo-
tency [19]. In terms of IPSC, although it is formally possible
to create IPSC without Myc [20, 21], the efﬁciency is dramat-
ically reduced by the omission of Myc and the timeframe for
appearance of colonies is greatly extended. In Yamanaka’s
groundbreaking IPSC paper, they reported being unable to
make IPSC without Myc [22] further suggesting Myc strongly
boosts IPSC formation. Thus, the stem cell ﬁeld is faced with
a catch-22 situation in that if one seeks to make stem cells
safer by lowering Myc levels, a tandem reduction in the
‘‘stemness’’ of those cells may prove inevitable. The same
appears to be true for other master stem cell regulators such
as KLF4. Lowered levels of KLF family members including
KLF4 substantially impaired ESC pluripotency and self-
renewal, forcing ESC to differentiate [23].
ARE PLURIPOTENCY AND TUMORIGENICITY
COUPLED?
The dualistic natures of Myc and KLF4, linked to both tumor-
igenesis and normal stem cell biology, highlight the more
general dilemma that the regenerative medicine ﬁeld faces in
trying to preserve self-renewal and pluripotency while elimi-
nating tumorigenicity. A fundamental principle of cell biology
may be that the greater the pluripotency and self-renewal
properties that a stem cell possesses, invariably the higher the
probability it will cause tumors (Fig. 1). Conversely, reducing
the tumorigenic nature of stem cells may inevitably reduce
the self-renewal and pluripotency of stem cells. Unfortunately,
this means that one may not be able to completely eliminate
the ability of a stem cell to cause tumors without robbing the
cell of identity, its stem-like nature. In other words, to make a
stem cell completely unable to cause tumors, you may have
to make that cell no longer be a stem cell. However, not all
stem cells even within the same culture have the ability to
form tumors suggesting that pluripotency and tumorigenicity
may not be so completely bound together. In this alternative
model, ‘‘stemness’’ and tumorigenicity are highly related pro-
cess, but separable and with important distinct molecular
features.
ANIMAL SAFETY MODELS:H OW TO
DISTINGUISH BETWEEN LACK OF STEM CELL
TUMORIGENICITY VERSUS HOST REJECTION?
Part of the challenge of resolving issues related to stem cell
safety is that only few in vivo studies have been reported,
particularly on human cells such as human ESC (hESC).
Some studies with introduction of hESC into animal models
have given apparently encouraging results. An example of
such a study was one where rats were given a hESC trans-
plant. They not only showed improvement of their Parkin-
son’s disease symptoms, but at least for the 3 months of the
study also did not develop detectable teratoma [24]. On the
other hand, another study using an animal model system and
stem cell transplant failed because of teratoma formation [25].
In all such studies, particularly with a ‘‘negative’’ result where
no teratoma were detected, it is unclear whether the apparent
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the transplanted stem cells or rather reﬂects the level of
immunosuppression in the animal model being used (i.e., a
false negative). Lack of teratoma in animal models with stem
cell transplants may most often be reﬂective of a failure of
engraftment due to immune cells in the host killing the stem
cells. Fortunately, new, improved humanized mouse model
systems are continually being developed that may be more
useful for assessing the tumorigenicity of stem cells [26].
Teratoma is not the only concern as hESC can also form
malignant tumors. A recent study found robust malignant tu-
mor-inducing capacity of hESC including H1 and HSF-6 [6].
IPSC can also form both teratoma as well as malignant
tumors such as neuroblastoma and follicular carcinoma [5].
Thus, the potential risk to human patients from both teratoma
and malignant tumors is quite real, yet remains difﬁcult to
estimate as no human trials of hESC or IPSC have been con-
ducted at this time.
PARALLELS BETWEEN INDUCED PLURIPOTENCY
AND ONCOGENIC TRANSFORMATION IN THE
FORM OF FOCUS FORMATION IN FIBROBLASTS
IPSC have been produced from a number of cell types, but
most often from ﬁbroblasts. The production of IPSC is eerily
similar in a number of ways to a tumor-formation assay called
‘‘focus formation’’ in ﬁbroblasts [27, 28] with both able to be
driven by Myc genes. Focus formation is an assay for testing
tumorigenicity of speciﬁc genes in ﬁbroblasts. In both focus
formation assays and IPSC induction, monolayer cultures of
ﬁbroblasts are transduced with retroviruses, some of which
encode oncogenes. The growth of cultures is continued at
high density without passaging. Normal cells undergo contact
inhibition and generally remain as a largely quiescent mono-
layer. In both IPSC and focus formation assays, the expecta-
tion is that at some point tightly packed growths of cells will
form above the monolayer. In each case, these ‘‘colonies’’ ex-
hibit escape from the normal quiescent state induced by con-
tact inhibition. Both IPSC and oncogenic foci are transferable
to form new cultures and both can cause tumors when
injected into immunocompromised mice. The parallels
between foci formation and IPSC production suggest these
processes are perhaps related to some extent. It is quite possi-
ble that a fraction of colonies that form during IPSC induction
are more similar to an oncogenic focus than an IPSC colony
and may very well be essentially tumor colonies. If so, studies
of these byproducts of the IPSC process may prove fruitful
for furthering our understanding of the links as well as differ-
ences between stem and tumor cells.
WILL NONGENETIC METHODS FOR PRODUCING
IPSC REDUCE THE RISK OF TUMORS?
If one accepts the model that making a cell more stem-like
predisposes that cell to cause a tumor, then IPSC are pre-
dicted to be inherently more tumorigenic than their nonstem
cells of origin such as ﬁbroblasts. However, even beyond this
kind of modeling there are compelling reasons for worrying
about IPSC tumorigenicity based on actual published data. Of
greatest concern is that nearly all IPSC described in published
works have been demonstrated to cause teratoma, proving
pluripotency but also tumorigenicity, and that mice geneti-
cally derived to contain some tissues from IPSC have a
malignant tumor incidence of 20% [29]. Genetic changes
intrinsic to the IPSC generation process may pose risk of
enhancing tumorigenesis through both the introduced genes
themselves and in theory via the potential changes at speciﬁc
integration sites.
The IPSC ﬁeld is evolving rapidly and moving away from
methods of induction that rely on genetic changes. This
approach is in its early days with some very promising initial
results [30, 31], but predictions are that such a move gener-
ally should reduce tumorigenicity and improve safety. How-
ever, important questions remain. Will it ever be possible to
make IPSC with absolutely no genetic changes? Can IPSC
ever totally escape from dependence (whether via genetic or
nongenetic approaches) on Myc, KLF4, and other possible
oncogenes? Although it may appear that the IPSC ﬁeld has al-
ready answered this afﬁrmatively for Myc in that IPSC can be
generated without added Myc, the omission of Myc reduces
the efﬁciency of IPSC generation and yet these IPSC can still
produce tumors in the form of teratoma [20, 21, 32]. These
studies also do not address the role of endogenous Myc. In
IPSC generated without genetic addition of Myc, the cells of
origin may well be characterized by unusually high levels of
endogenous Myc proteins required for the reprogramming and
could make the cells prone to tumorigenesis.
PROPOSING AN ALTERNATE ASSAY OF
TUMORIGENICITY FOR IPSC AND OTHER
STEM CELLS
To gauge the tumorigenic nature of IPSC most often research-
ers have used what will be termed the derived mouse assay.
In this assay, through mouse genetics IPSC are used to con-
tribute to the formation of chimeric mice in which some tis-
sue lineages are derived from IPSC. The mice are then stud-
ied for tumor development. Using this assay, IPSC have been
reported to cause malignant tumors in up to 20% of such
derived mice [5], whereas IPSC generated without exogenous
Myc have been reported to not form tumors [20, 32]. The
Figure 1. The relationship between pluripotency and tumorigenicity.
Biological (top) and molecular (bottom) links between pluripotency
and tumorigenicity are described. Abbreviations: EC, embryonic
carcinoma cells; hESC, human embryonic stem cells; IPSC, induced
pluripotent stem cells.
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reactivation of Myc from previously silenced viral insertions.
The problems with the derived mouse assay are twofold. First,
the IPSC must go through early embryogenesis and are sub-
ject to the powerful embryonic reprogramming forces that are
predicted to dramatically reduce the apparent tumorigenicity
of the cells. Second, the derived mouse system for studying
IPSC tumorigenicity bears no resemblance to how cells would
be used in regenerative medicine where they would either be
focally injected in a site to be repaired or administered intra-
venously (IV). Both focal injection and IV administration of
IPSC as a means for studying IPSC tumorigenicity have not
been reported in the literature. Unfortunately, these assays are
expected to show higher rates of tumorigenicity than the
derived mouse assay, but more accurately reﬂect risk to
patients. Another problem with the derived mouse assay is
that currently it is unusable for studying tumorigenicity of
human IPSC. Researchers appear to be disinclined to put
human IPSC into mouse embryos, perhaps due to the ban on
putting hESC into a mouse embryo and taking it beyond day
8 of growth. Thus, other than their robust teratoma inducing
abilities, the reality is that the stem cell ﬁeld knows almost
nothing about the tumorigenicity of mouse IPSC and essen-
tially nothing about that of human IPSC in a context relevant
to regenerative medicine.
‘‘THESE STEM CELLS LOOK TOO GOOD TO BE
NORMAL’’: COMMON PRACTICES WORSEN THE
INHERENT TUMORIGENICITY OF STEM CELLS
Although stem cells have an intrinsic predisposition to caus-
ing tumors under certain conditions, this predilection can eas-
ily but unknowingly be enhanced by how the stem cells are
grown by researchers. The simple act of removing stem cells
from organisms and growing them in culture profoundly
changes the biology of the cells in ways that makes them
more tumorigenic. Although the hematopoietic stem cells in
bone marrow can be in essence directly transplanted to
patients without loss of repopulating activity, in most cases
the in vitro culture of stem cells is an unavoidable step. Fur-
ther, the rate of a surprisingly large number of genomic alter-
ations (reviewed in [33]) increases with time in culture and is
at least one general mechanism of enhanced tumorigenicity
[34]. The karyotypic alterations in cultured hESC have been
proposed to mirror tumorigenic events that occur in vivo [33]
and to at least in part contribute to tumorigenicity through
enhanced proliferation. In general, the tumorigenicity of stem
cells is predicted to increase proportionately with the length
of time that they are cultured. An exception to this is mesen-
chymal stem cells (MSC), which appear to be culturable for
weeks without clear adverse consequences. A long-term study
MSC found a very positive biosafety proﬁle [35] and MSC
are currently in clinical trials with encouraging results
(reviewed in [36]). Thus, more generally stem cells other than
IPSC and ESC may prove more amenable to culturing, but
problems such as karyotypic changes can also occur in these
other stem cells indicating that minimizing culture time
should always be a key objective.
The ‘‘best’’ ESC are often considered to be those that
grow fairly rapidly, form tightly packed colonies, have a low
rate of spontaneous differentiation, and are readily passage-
able. As researchers grow ESC, there may be a tendency to
selectively propagate colonies and even work with ESC lines
that more generally ﬁt the above criteria. Such ESC are
almost certain to be endowed with speciﬁc molecular charac-
teristics that make them easier to grow, but at the same time
the traits described earlier, when selected for, may tend over
time to enrich for stem cells that have enhanced tumorigenic-
ity. Interestingly, a recent study indicates that hESC cultures
are heterogenous, containing cells with widely varying tumor-
igenicity and some variant sublines were isolated with
enhanced tumorigenicity [37]. Although this complicates the
picture of hESC-based regenerative medicine, it also suggests
an opportunity for isolating variants that possess low or
absent tumorigenicity. Paradoxically, the best ESC for regen-
erative medicine may be the hardest to propagate because
they exhibit the following properties: slow growth, a high rate
of spontaneous differentiation, and low colony forming poten-
tial. Thus, the safest ESC for regenerative medicine therapies
are predicted to be those that are the most difﬁcult to culture
and the easiest to culture may be the least safe.
AN UNANTICIPATED RISK FROM INDUCED
EPIGENETIC CHANGES?
Mostly under the radar in the ﬁeld of stem cell safety are
potential undesirable side effects of epigenetic changes in
IPSC and hESC that are undetectable by karyotyping, but
could have profound effects on cell biology as the biology of
normal hESC is regulated by epigenetic programming [38].
Epigenetic changes are also postulated to play a key role in
the reprogramming at the heart of IPSC formation [11, 12]
and are modeled to be instrumental in creating IPSC both
with or without genetic changes, particularly in the latter
case. Thus, it is critically important to more fully study the
global epigenetic changes associated with pluripotency and
especially induced pluripotency, even if IPSC are ultimately
produced without genetic changes. Epigenetic alterations may
in part confound the efﬁcacy of moving away from genetic
changes through promoting tumorigenesis themselves. Such
changes also occur during establishment and passaging of
hESC [39], whose epigenome is highly unstable [40], almost
certainly enhancing tumorigenicity. Characterizing the rela-
tionships among the epigenome, pluripotency, and tumorige-
nicity should prove of great beneﬁt for developing safe regen-
erative medicine.
APPROACHES TO SAFE STEM CELL-BASED
REGENERATIVE MEDICINE THERAPIES
The four most promising approaches to make stem cell-based
regenerative medicine safer are discussed here (Fig. 2). Some
pretransplant screening is applicable to all four approaches.
Safety screening could encompass everything from assays of
genome integrity (chromosome number, deletions, and dupli-
cations) to gene expression array proﬁling as well as micro
RNA patterns and perhaps even epigenetic screening. These
approaches should enhance the safety of any regenerative
medicine therapy.
Transplants of Progenitors
In a general sense, the reason that relatively ‘‘normal’’ stem
cells such as ESC can in turn still cause tumors is because
they are programmed to be robust tissue and organ growers.
Tumors are abnormal organs or tissues, which a growing
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and perhaps are maintained via their own population of stem
cells. The notion that a wide variety of tumors beyond those
such as teratocarcinoma and teratoma may contain stem cells
is gaining widespread acceptance (reviewed in [41]). These
tumor or cancer stem cells, also termed tumor-initiating cells,
seem to share many traits with normal stem cells, but are pre-
dicted to have at least partially impaired pluripotency. In that
sense, tumor stem cells may be akin to racecars with accelera-
tors (indeﬁnite self-renewal potential) but bad brakes (differ-
entiation potential/pluripotency).
The simplest way to slow or even eliminate the tumorige-
nicity of normal stem cells prior to transplantation may be to
take advantage of their natural ‘‘brakes’’ or pluripotency by
partially differentiating them into progenitors. Therefore, a
promising proposed method for making stem cell-based re-
generative medicine therapies safer may seem paradoxical: to
not transplant stem cells at all into patients. This avenue has
gained wide acceptance as the most promising approach to re-
generative medicine. The idea is to use the stem cells to pro-
duce progenitor or precursor cells of the desired lineage and
then transplant progenitors puriﬁed by sorting (Fig. 2). On
January 23, 2009 such an approach was given approval by the
Food and Drug Administration based on hESC-derived oligo-
dendrocytes. With sufﬁcient purity, weeding out through dif-
ferentiation coupled with sorting all or nearly all contaminat-
ing stem cells that remain, the progenitor transplant should be
both safe and effective. The sorting could be either positive
(sorting for the progenitors based on markers) or negative
(sorting via stem cell markers for their elimination). Because
differentiation is a dynamic process, not an ‘‘on/off’’ switch,
there will always be residual stem cells remaining in differen-
tiated cultures and sorting is not perfect. Thus, the most prac-
tical approach to safe regenerative medicine would be some
combination of differentiation, sorting, and one of the two
general approaches outlined below (ﬁrst two subsections) to
kill residual stem cells.
It remains unknown just how pure the progenitors must be
to be safe. How few remaining stem cells are enough to cause
concern about tumors? If the answer is ‘‘zero,’’ then it may be
difﬁcult to achieve this goal because the reality is that the
only pure cell population is that consisting of a single cell. It
seems much more probable that the presence of a few stem
cells may not pose a serious risk. However, the remaining un-
differentiated stem cells may be unique and have a much
higher risk of generating a tumor because they in some man-
ner escaped being differentiated, perhaps reﬂecting a partial
impairment of pluripotency that brings them one step closer
to a tumorigenic phenotype. The few published studies
addressing this question leave the issue largely unresolved.
For example, a study of use of hESC for Parkinsonian rats
found that differentiation of the cells prior to transplant
lowered the incidence of teratoma [42]. However, high lev-
els of natural killer (NK) cells in many rat and mouse ani-
mal models appear to kill most or all injected stem cells,
questioning the validity of such safety studies when results
are negative. Further complicating the story is the observa-
tion that ESC are in fact more susceptible to killing by NK
cells than are differentiated ESC due to differences in cell
surface proteins [43].
Figure 2. Methods to address stem cell tumorigenicity to develop safe regenerative medicine therapies. Four possible approaches are outlined.
‘‘Stemotoxic’’ refers to agents or methods that are speciﬁcally toxic to and hence kill stem cells.
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The stable genetic introduction of a suicide gene such as thy-
midine kinase (tk) into stem cells has been reported to be
effective in combination with Ganciclovir (Gan) treatment
[44]. However, in this study, the treatment was not stem cell
speciﬁc and would have also killed any differentiated progeny
from those stem cells in a hypothetical treatment situation
causing it to fail. Differentiated teratoma cells were also read-
ily killed by Gan treatment. Nonetheless, relatively simple
modiﬁcations, such as using oct3 or nanog promoter driven
expression of tk, would make the system more stem cell spe-
ciﬁc to ideally kill only those hESC that have escaped differ-
entiation. Of concern is the fact that it remains unknown if all
hESC express what are thought of as the key stem cell factors
such as oct3 and nanog. Although populations of hESC do
express these seemingly without exception, it is unclear
whether small, but functionally relevant subpopulations may
not. Another open question is whether transplantation of
hESC and engraftment of hESC in the host could lower or
shut off expression of suicide genes driven by stem cell pro-
moters either immediately following transplant or at a much
later date. Even with efﬁcient stem cell killing, the possibility
of patients requiring life-long treatment with Gan or other
agents to suppress growth of residual stem cells raises the
issue of possible reemergence of proliferating, drug-resistant
stem cells possibly in turn leading to tumors at later dates.
The major concern with the suicide gene approach is its
requirement for genetically modifying the stem cells, which
could raise the risk of tumorigenicity from the beginning.
However, a recent study of the safety of viral transduction of
human hematopoietic stem cells and MSCs in which animals
were followed for up to 18 months found no evidence of tu-
morigenesis, suggesting that limited genetic modiﬁcation of
the type needed to introduce a single suicide gene may be
safe [35]. If clonal hESC derivatives can be produced, viral
integration sites can be mapped to ensure that they are at the
very least in noncoding genomic locations and ideally at a
large distance from genes, further enhancing safety. Similarly,
it is possible that viral vectors can be designed to integrate
with a high frequency at speciﬁc sites at regions distant from
genes.
Directed Killing of Residual Stem Cells Based on a
Nongenetic Method
If the safety of stem cells with introduced suicide genes turns
out to be a serious obstacle, other approaches for weeding out
residual stem cells may be needed. Although it is formally
possible that patients receiving a stem cell-based regenerative
medicine therapy could be treated with a broad-spectrum che-
motherapeutic agent (chemo) postdifferentiation, for many al-
ready ill patients such treatments may be too toxic and it is
unclear how effective they would be at killing residual stem
cells, particularly if they were temporarily dormant. Although
hESC and IPSC are rapidly growing cells that should in
theory be killed by chemo, residual stem cells from an hESC
or IPSC transplant may very well take on a quiescent, chemo-
resistant character in vivo. Thus, much more speciﬁc killing
of residual stem cells is desirable. The most promising
approach to this end is to use killer antibodies directed against
antigens present on the surface of hESC such as SSEA-4 or a
member of the TRA family. New hESC surface antigens are
currently being discovered and tested such as podocalyxin-
like protein-1, which appears quite promising as a cytotoxic
agent speciﬁcally against undifferentiated hESC [45]. One
major concern with this ‘‘stemotoxic’’ approach is how spe-
ciﬁc these methods would be at targeting stem cells as
opposed to other cell types. Also, would the antistem cell
treatments have to be continued in the patient and with what
side effects? What would be the consequences if these treat-
ments killed a signiﬁcant number of endogenous stem cells in
speciﬁc organs in the patient? At this time too little is known
about the possible expression of the targeted antigens in adult
stem cells and it remains a serious concern.
Use Stem Cells Themselves for transplant, but First
Eliminate Tumor Forming Potential Without
Genetic Modiﬁcation
In theory, the simplest approach to regenerative medicine and
the one expected to lead to robust regenerative tissue growth
would seem to be to use stem cells themselves, but ones that
had been treated in such a way that they were no longer
tumorigenic. Of course, at this time no such methodology
exists and the notion of using stem cells directly for trans-
plants would appear to be strongly out of favor with regula-
tors due to the robust ability of hESC to form teratoma [46].
A similar conceptual kind of approach, selective purging
of malignant cells from bone marrow leading to enhance safe
transplantation of hematopoietic stem cells, has not consis-
tently been effective (reviewed in [47]), but that may be a
much taller order since malignant cells are already abundant.
There remains hope more generally that mixed populations of
tumorigenic and nontumorigenic stem cells may be separable
or that the tumorigenic subpopulation may be selectively tar-
getable. Further, as mapping continues of the molecular
mechanisms by which stem and tumor cells are programmed,
differences will continue to be revealed and those unique
traits may pave the way for approaches to eliminate tumorige-
nicity while preserving pluripotency.
FUTURE DIRECTIONS
The road from where we are today to a future with IPSC- and
hESC-based regenerative medicine therapies being safe and
more common treatment modalities is not a clear, linear one.
However, basic and translational studies into the tumorigenic
nature of stem cells are going to be collectively an essential
bridge to cross along the way. Further advances in our under-
standing of tumor stem cells and tumorigenesis more gener-
ally will also provide additional fuel for these advances.
Finally, a much more open discussion and investigation of the
tumorigenic nature of stem cells than has yet to occur, partic-
ularly that of IPSC and hESC, will undoubtedly prove essen-
tial for the development of safe and effective regenerative
medicine therapies.
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